Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Intellia from a "sell" to a "hold"; overall analyst coverage is mixed (11 buys, 10 holds, 3 sells) with a MarketBeat consensus target price of $18.43.
• Shares and recent results: NTLA opened at $9.61 (market cap $1.11B) and, while it posted an EPS beat last quarter and revenue rose 51.6% year-over-year, the company remains deeply unprofitable with a very negative net margin and analysts forecasting materially negative EPS for the year.
• Pipeline and ownership: Intellia is a genome-editing company advancing in‑vivo programs (NTLA‑2001, NTLA‑2002, NTLA‑3001), with insiders owning about 3.1% and institutional investors holding roughly 88.8% of the stock.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Monday.

NTLA has been the topic of a number of other research reports. HC Wainwright dropped their price target on Intellia Therapeutics from $18.00 to $15.00 and set a "buy" rating on the stock in a research note on Monday, November 10th. Citizens Jmp decreased their target price on shares of Intellia Therapeutics from $29.00 to $21.00 and set a "market outperform" rating for the company in a report on Friday, November 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Intellia Therapeutics in a report on Wednesday, October 8th. Chardan Capital reduced their price target on shares of Intellia Therapeutics from $48.00 to $26.00 and set a "buy" rating for the company in a research report on Friday, November 7th. Finally, Guggenheim cut shares of Intellia Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday, October 27th. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $18.43.

Intellia Therapeutics Trading Down 1.3%

NASDAQ:NTLA opened at $9.61 on Monday. The company has a 50-day moving average of $15.33 and a 200-day moving average of $12.59. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -2.25 and a beta of 2.13. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The business had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. During the same period in the previous year, the firm earned ($1.34) EPS. The business's revenue for the quarter was up 51.6% on a year-over-year basis. On average, research analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In other news, CAO Michael P. Dube sold 1,871 shares of the business's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares in the company, valued at approximately $960,523.08. The trade was a 3.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds have recently made changes to their positions in NTLA. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics during the second quarter worth about $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Whipplewood Advisors LLC increased its position in shares of Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company's stock valued at $32,000 after purchasing an additional 3,447 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock valued at $33,000 after purchasing an additional 1,655 shares in the last quarter. Institutional investors own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.